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The incidence of adult urolithiasis has increased significantly
in industrialized countries over the past decades. Sound
incidence rates are not available for children, nor are they
known for nephrocalcinosis, which can appear as a single
entity or together with urolithiasis. In contrast to the adult
kidney stone patient, where environmental factors are the
main cause, genetic and/or metabolic disorders are the main
reason for childhood nephrocalcinosis and urolithiasis.
While hypercalciuria is considered to be the most frequent
risk factor, several other metabolic disorders such as
hypocitraturia or hyperoxaluria, as well as a variety of renal
tubular diseases, e.g., Dent’s disease or renal tubular acidosis,
have to be ruled out by urine and/or blood analysis.
Associated symptoms such as growth retardation, intestinal
absorption, or bone demineralization should be evaluated
for diagnostic and therapeutic purposes. Preterm infants
are a special risk population with a high incidence of
nephrocalcinosis arising from immature kidney, medication,
and hypocitraturia. In children, concise evaluation will reveal
an underlying pathomechanism in 475% of patients.
Early treatment reducing urinary saturation of the soluble
by increasing fluid intake and by providing crystallization
inhibitors, as well as disease-specific medication, are
mandatory to prevent recurrent kidney stones and/or
progressive nephrocalcinosis, and consequently
deterioration of renal function.
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In the past decade, a significant increase in both incidence
and prevalence of adult urolithiasis (UL) has been noted
in industrialized countries. In addition, in pediatric patients,
hospitalization for kidney stone disease has steadily incre-
ased.1,2 Definite incidence rates are, however, not available
for UL, nor for nephrocalcinosis (NC) in children. The
increase of stone disease in adults was most likely related to
(changing) environmental factors such as dietary habits, fluid
intake, and obesity, all subsumed in the metabolic syndrome.
Although this will clearly also gain importance in the
pediatric population, genetic and anatomical causes are still
the main determinants. UL subsumes stones formed in the
kidney but localized anywhere in the urinary tract, as well
as primary bladder stones3 (Figure 1a). Nephrolithiasis
describes stones residing in the kidney (Figure 1b–d). NC
comprises deposits of calcium salts in the tubules, the tubular
epithelium, and/or the interstitial tissue of the kidney3
(Figure 1e). Although the composition of the deposits mostly
remains unclear and cannot be identified by ultrasound,
pathologists distinguish between NC due to calcium
phosphate and oxalosis due to calcium oxalate deposition.
NC can also be classified according to the anatomic area
involved. Medullary NC, subdivided into three subtypes
according to the degree of echogenicity, is distinguished from
cortical (e.g., in acute cortical necrosis) and diffuse NC.4,5
EPIDEMIOLOGY
Adult data describe an incidence of UL of approximately
1.5% and a prevalence of 5.2%.6,7 About 12% of men and 5%
of women in industrialized countries will therefore develop a
kidney stone at least once in their life.8 The incidence of UL
in pediatric patients is considered to be approximately 10%
of that in adults. As incidental discovery occurs in 15–40% of
children due to the high proportion of unspecific symptoms,
the real incidence in childhood is likely to be underestimated.
During past decades, studies reported that 1 in 1000 to 1 in
7500 pediatric hospital admissions were related to UL.9,10 A
recent single-center study reported a nearly fivefold increase
in hospital admissions for pediatric UL during the past
decade.1 Another study from the southeast United States,
known as the US ‘stone-belt’, identified an increase of
children with UL in an Emergency Room setting from 7.9 to
18.5 per 100,000 from 1996 to 2007. Interestingly, the
number of African-American children remained relatively
low, 3.2 to 4.5, whereas the number of Caucasian children in
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that setting rose from 10.9 to 26.2 per 100,000 in 2007.
Caucasian children are thus 5.6 times more likely to have
kidney stones compared with African-American children.2
SEX AND AGE
UL and/or NC affect children of all ages.11 NC seems to
primarily appear in the first years of life, which might be
due to the fact that it is frequently based on tubulopathies
or inborn errors of metabolism (Table 1). Sound data on
sex and age distribution are, however, only known for UL.
Younger children are described to present with a higher
proportion of renal calculi,12–14 whereas older children rather
present with ureteral stones. Contradictory data exist on a
higher or equal probability of spontaneous passage in
children older or younger than 10 years of age.13,14 Data on
sex distribution have changed over the past years. In adults, a
male predominance is no longer found. Interestingly, the risk
of stone disease due to increased body mass index and waist
circumference is more pronounced in women.15–18 A recent
study analyzed the Kids’ Inpatient large-scale pediatric
database for sex distribution in more than 2 million children
hospitalized because of UL and reported a changing sex
distribution according to age.19 Boys were more frequently
affected during the first decade (1.2:1 for 0–5 years, 1.3:1 for
6–10 years), whereas girls were more frequently affected
during the second decade of life (0.96:1 for 11–15 years, 0.3:1
for 16–20 years).19 Data from the southeast United States
show even more pronounced changes in sex distribution.
Whereas in 1996 the reported incidence in boys (8.0/100,000)
did not differ from that in girls (7.7/100,000), the incidence
in girls showed a faster and stronger increase to 21.9/100,000
in 2007 (boys 15.3/100,000).2
ETIOLOGY
Compared with adults, children are more likely to have an
underlying metabolic disorder, and subsequently a higher
GE
L7 0
21 KG
RE
2
4
6
≅
Vol.
> Diam 1 = 8. 10 cm
LI
Diam 2 =  cm
Diam 3 =  cm
Volumen =  cc
0
2
4
6
8
GE
L7
Figure 1 |Urolithiasis and/or nephrocalcinosis in different diseases. (a) Bladder stone in a 4-year-old patient with Joubert syndrome
after kidney transplantation due to suture in situ; (b) infectious stones (mixture of struvite and carbonate apatite) in a 9-month-old boy
with recurrent urinary tract infections (Proteus mirabilis) and proximal ureter stenosis; (c) staghorn calculus and nephrocalcinosis in a
7-year-old patient with cystic fibrosis, hyperoxaluria, and hypocitraturia; (d) kidney stones and nephrocalcinosis in an 11-year-old patient
with primary hyperoxaluria type I; and (e) nephrocalcinosis in a 2-year-old patient with familial hypomagnesemia, hypercalciuria,
and nephrocalcinosis syndrome.
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Table 1 | Genetic diseases with urolithiasis and/or nephrocalcinosis according to underlying metabolic derangement
Entity/disorder Gene/gene product/locus Inheritance Hints and hallmarks
Hypercalciuria
Autosomal dominant
hypocalcemic hypercalciuria48
CASR/CaSR, 3q21.1
Gain-of-function mutations usually
private mutations leading to leftward
shift of extracellular calcium
dose–response curve
ad Mild, usually asymptomatic hypocalcemia, hyper-
calciuria, with elevated serum phosphate and low
serum magnesium levels, PTH in the low-normal range
nota bene: vitamin D substitution will result in excess
hypercalciuria, leading to NC, UL and eventually CRF
note: inactivating mutations of CaSR increase the
threshold for negative feedback and cause
hypocalciuric hypercalcemia
Hypercalcemia with
hypercalciuria169-familial isolated
hyperparathyroidism
Menin, 11q13
Parafibromin, 1q31.3
CaSR, 3q21.1
ad Familial isolated parathyroid tumors, inactivating
mutations in CaSR
Idiopathic hypercalciuria170–172 SAC/soluble adenyl cyclase,
1q23.3–q24; sequence variations but
no causative mutations
ad Associated with absorptive type of hypercalciuria,
normocalcemia, normal PTH levels, low bone mineral
density
VDR/Vitamin D receptor, 12q12–q14,
polymorphisms, but no causative
mutations
ad Associated with resorptive type of hypercalciuria
Gene remains to be found,
9q33.2–q34.2 locus
ad Autosomal dominant nephrolithiasis
BS169
Type 1 SLC12A1/NKCC2 (bumetanide-sodium-
potassium-chloride cotransporter);
15q15–q21.1
ar Classical BS: hypokalemic alkalosis, renal salt wasting,
hyperreninemic hyperaldosteronism,
hyperprostaglandinemia, hypercalciuria and NC,
potential CRF antenatal BS (polyhydramnios, salt
wasting, prematurity, volume depletion)
Type 2 KCNJ/ROMK (renal outer-medullary
potassium channel); 11q24
ar Classical/antenatal BS, hypercalciuria and NC transient
neonatal hyperkalemia later evolving into (modest)
hypokalemia, potential CRF
Type 3 CLCNKB/CLC-Kb (voltage-gated
chloride channel); 1q36
ar Mostly classical BS, wide phenotype variation
(diagnosis neonatal period to adulthood), less
hypercalciuria and NC, potential CRF
Type 4 BSND/Barttin; 1q31 ar Usually severe antenatal BS with sensorineuronal
deafness, but less hypercalciuria and NC, CRF
Type 5 CASR/CaSR, (severe gain-of-function
mutations); 3q21.1
ad Early (symptomatic) hypocalcemia and hypercalciuria
with NC (see above) followed later by classical BS
features
Dent’s disease
Dent 1 (ref. 53) CLCN5 chloride/proton antiporter CLC5;
Xp11.22 (Dent 1), mutations in 60% of
cases
Xr Male gender, FS (aminoaciduria, phosphaturia,
glycosuria, kaliuresis, impaired acidification), LMW
proteinuria, hypercalciuria (less severe with age),
NC/UL, CRF regular
Dent 2 (ref. 173) OCRL1 (Dent 2), mutations in 15%
of cases
Xr Patients with OCRL1 mutation and Dent’s disease lack
cataracts (BS-like phenotype termed BS type 6 was
reported in a single Turkish patient with CLCN5
mutation)
Lowe’s (oculorenocerebral)
syndrome174
OCRL1/phosphatidylinositol-4,5-
biphosphate-5-phosphatase ocrl1;
Xq25
Xr Male gender, congenital cataracts, mental retardation,
hypotonia, rickets, proximal tubular defect
(bicarbonate, phosphate, aminoaciduria), nephrotic
range proteinuria, metabolic acidosis, hypercalciuria
and NC/UL, CRF regular
Urolithiasis, osteopetrosis and
persistent hypophosphatemia175
NPT2a/sodium-phosphate-
cotransporter type 2a (SLC34A1); 5q35
ad Excess urinary phosphate excretion,
hypophosphatemia, elevated 1,25OH vitamin D,
elevated AP, suppressed PTH, hypercalcemia and
hypercalciuria
Hereditary hypophosphatemic
rickets with hypercalciuria176
NPT2c/sodium-phosphate-
cotransporter type 2c (SLC34A3); 9q34
ar Excess loss of urinary phosphate, hypophosphatemia,
severe rickets, hypercalciuria but no hypercalcemia,
UL
Williams–Beuren syndrome177 Continuous gene deletion syndrome
(1.55 Mb, including ELN, LIMK1, RFC2);
7q11.23
Mostly
sporadic
Multisystemic developmental disorder with mental
retardation, distinctive neuropsychological profile
‘happy party manner’, variable cardiovascular findings
(aortic stenosis), abnormalities of renal tract and
connective tissue, temporary hypercalcemia and
hypercalciuria, NC/UL
Table 1 Continued on following page
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Table 1 | Continued
Entity/disorder Gene/gene product/locus Inheritance Hints and hallmarks
Familial hypomagnesemia with
hypercalciuria and
nephrocalcinosis (FHHNC)178
CLDN16/claudin 16/paracellin 1; 3q27 ar Symptomatic hypomagnesemia and hypocalcemia,
hypercalciuria and NC/UL, distal RTA, regular CRF
FHHNC with ocular
involvement179
CLDN19/claudin 19; 1p34.2 ar Hallmarks of FHHNC with multiple ocular
abnormalities
Wilson’s disease14 ATP7B/copper transporting ATPase 2;
13q14.3
ar Fanconi syndrome, liver dysfunction, neurological
symptoms, Kayser–Fleischer cornea ring, elevated
urinary copper excretion-reduced ceruloplasmin,
hypercalciuria, UL, NC, CRF
Tyrosinemia type 1 (ref. 14) FAH/fumarylacetone-acetate hydrolase;
15q.23–q25
ar Fanconi syndrome, rickets, liver failure, coagulopathy,
hypercalciuria, UL, NC, CRF
Liddle’s syndrome
(pseudohyperaldosteronism
type 1)14
SCNN1B and SCNN1G/b- and g-subunits
of epithelial sodium channel (ENaC);
16p12
ad Rare, triad of hypokalemia, alkalosis and sodium-
sensitive hypertension, suppressed aldosterone
levels, hypercalciuria and NC, risk of CRF, treatment
with amiloride (ENaC blocker)
Gordon’s syndrome
(pseudohypoaldosteronism
type 2)14
WNK1 12p13.3, WNK4 17q21.31/serine-
threonine kinase
ad Hyperkalemia, metabolic acidosis (reduced
ammonium excretion), hypertension and
hypercalciuria (RTA type 4)
Hyperoxaluria
Primary hyperoxaluria
type I (PH I)76
AGXT/alanin-glyoxylate-
aminotransferase; 2q37.3
80–90% of PH cases
ar Recurrent UL and/or progressive NC, UTI, severe
hyperoxaluria (41 mmol/1.73 m2 per day),
hyperglycolic aciduria, ESRF regular outcome
(neonatal period to late adulthood), systemic oxalate
deposition with advanced renal failure leads to a
multisystemic disease character
Primary hyperoxaluria type II
(PH II)85
GRHPR/glyoxylate reductase/
hydroxylpyruvate reductase (GRHPR);
9q11, 10% of PH cases
ar Hallmarks recurrent UL, NC less frequent,
hyperoxaluria plus marked L-glyceric aciduria in most
cases, lower (B20%) risk of ESRF
Primary hyperoxaluria type III
(PH III)85
DHDPSL/4-hydroxy-2-oxoglutarate
aldolase; 10q24.2
ar Likely the second most frequent PH type disease
seems to remit with age.
No case of ESRF reported (nota bene: very
limited data)
Atypical PH Unknown, negative AGXT, GRHPR,
and DHDPSL mutational analysis
Hyperoxaluria and clinical features overlapping
with PH type I–III
Risk of ESRF not defined
Cystinuria
Cystinuria type I (heterozygotes
are silent)180
SLC3A1/rBAT; 2p16.3, causative
mutations result mostly in type I
ar Impaired renal transport of cystine and dibasic amino
acids, high urinary cystine levels
Cystinuria type II (heterozygotes
show a variable degree of
hypercystinuria)180
SLC7A9/b0,+ AT; 19q13.1, causative
mutations may result in type I
phenotype
adip
Mixed type I/II cystinuria
phenotype180
All genotypes possible but mostly
SLC7A9 mutations
Hyperuricosuria
Lesch–Nyhan syndrome181 HPRT/hypoxanthine-guanine-
phosphoribosyltransferase; Xq26
Xr Symptomatic in males, normal at birth followed by
progressive psychomotor delay, gout,
hyperuricosuria, recurrent UL, automutilation
Partial HPRT deficiency181 Hyperuricosuria, wide spectrum of symptoms with
asymptomatic course in less severe forms
Glycogenosis type 1a182 G6PC/glucose-6-phosphatase; 17q21 ar Episodic severe hypoglycemic, lactic acedemia,
hyperuricosuria, hypercalciuria, hypocitraturia,
recurrent UL, NC, Fanconi syndrome, FSGS, renal
amyloidosis, CRF
Hypouricosuria
APRT deficiency183 APRT/adenine-
phosphoribosyltransferase; 16q24.3
ar Urinary accumulation of the insoluble purine 2,8
dihydroxyadenine (round + brown crystals), UL, CRF
Xanthinuria110 XDH/xanthine dihydrogenase oxidase;
2p22 (type 1)
Type 2 dual deficiency of XDH plus
aldehyde oxidase
ar Noticeable low levels of uric acid in serum and urine,
xanthinuria, UL (radiotransparent)
Urate transporter 1 (ref. 184) SLC22A12/renal urate anion exchanger
URAT1; 11q13
ar Sporadic/familial renal hypouricemia, UL, and risk of
exercise-induced ARF
Table 1 Continued on following page
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risk of stone recurrence16,17 or progression of NC3,4 (Table 1).
Hence, the identification of metabolic abnormalities that
predispose to UL/NC is imperative to prevent stone
recurrence, which is reported in up to 20–48% of children,
or rapid progression of NC.10,12,20,21 A urinary (metabolic)
risk profile was found in up to 76% of children with UL.14,22
NC does not necessarily lead to renal calculi, and UL may
occur in the apparent absence of (macroscopic) NC.23
Nevertheless, they may appear together in the same patient11
(Figure 1c, d). The ultrasound picture may suggest NC, but
the correct diagnosis would be microcalculi, which may be
visualized as tiny hyperechoic spots ofo3mm in diameter on
ultrasound, or as small stones of a diametero2mm on a low-
enhanced computed tomography (CT) or by endoscopic
examination.24–26 Laterality of NC in kidney stone formers
was also just recently described.27 Distinguishing both entities
may be problematic even with newer imaging techniques, and
hence endoscopic inspection of the papillae may be the only
option to truly verify the accurate diagnosis of NC.27 It was
reported that NC may disappear over time;28,29 however, this
was only determined by repeated ultrasound examinations.
Risk factors for UL/NC include genetic abnormalities in
epithelial transport, metabolic disturbances, anatomical
abnormalities, and urinary tract infections in the majority
of pediatric patients. Environmental factors mainly reflected
by diet definitively contributed more to the increasing
incidence of stone disease in adults, but may gain importance
in the pediatric population in the near future, expressed
by the increasing numbers of children with obesity or the
metabolic syndrome.30–32
Great progress has been made in understanding the
pathophysiology of stone disease. Randall33 was the first to
describe growing calcium oxalate stones attached to areas of
the papillae containing interstitial apatite deposits, which was
later confirmed by Evan et al.24 This stone formation/
overgrowth on interstitial apatite plaques (Randall’s plaques)
has recently been described by Coe et al.34 as the first of
three possible pathways leading to stone formation. Although
this pathway is typical of idiopathic calcium oxalate stone
formers, crystal deposition in renal tubules is found in nearly
all (other) stone-forming groups. As a third pathway, free
solution crystallization is described to be typical of patients
with cystinuria or those with secondary hyperoxaluria.34
Two crucial processes are believed to form the basis for the
development of NC: (1) crystal formation in renal tubules
and (2) crystal retention in the distal tubule. In case of an
increased bout of lithogenic factors or decreased urine
volume, urinary supersaturation leads to crystal formation
in the renal tubules. If supersaturation does not exceed a
certain (individual) level and duration, non-adherent epithe-
lium, as well as tubular transport mechanisms controlling
urine composition and adding crystal inhibitors such as
citrate, magnesium and proteins, allow passage of super-
saturated urine as well.35–41 In the absence of a non-adherent,
healthy epithelium or in case of failure of these protective
tubular mechanisms, crystal retention occurs. This takes
place in proliferating or regenerating cells in the distal
nephron, which luminally express hyaloronan and osteopon-
tin. The concept of immature/proliferating cells being prone
to retain crystals is in accordance with the observation that
Table 1 | Continued
Entity/disorder Gene/gene product/locus Inheritance Hints and hallmarks
RTA hypocitraturia + hypercalciuria
RTA54,185,186
RTA type 1 ATP6V1/B1 subunit of H+ ATPase;
2cen–q13
ar Distal RTA, metabolic acidosis (impaired H+ excretion)
of early onset with early NC and hearing loss,
hypocitraturia, hypercalciuria, UL, NC, hypokalemia,
rickets, failure to thrive
ATPV0A4/ A4 subunit of H+ ATPase;
7q33–34
ar Later onset of sensorineural deafness (sometimes
normal hearing)
SLC4A1/basolateral Cl/HCO3 exchanger
AE1; 17q21–22
ad Distal RTA of later onset, milder metabolic acidosis,
urine pH46.1, hypokalemia, hypocitraturia,
hypercalciuria, UL, NC, sometimes rickets
SLC4A1/basolateral Cl/HCO3 exchanger
AE1; 17q21–22
ar Distal RTA of childhood onset, metabolic acidosis plus
hemolytic anemia in southeast Asians
RTA type 2 SLC4A4/NBC1 sodium bicarbonate
cotransporter; 4q21
ar Proximal RTA, (milder) metabolic acidosis by
bicarbonate wasting, hypokalemia, growth
retardation, ocular abnormalities, enamel defects,
intellectual impairment, less severe hypercalciuria and
hypocitraturia
RTA type 3 (mixed type) CA2/carboanhydrase 2 ar Bicarbonate wasting + inability to acidify the urine:
RTA plus osteopetrosis (Guibaud–Vainsel syndrome),
intracerebral calcification, growth failure, intellectual
impairment, conductive deafness
Abbreviations: AD, autosomal dominant; ADIP, autosomal dominant with incomplete penetrance; AP, alkaline phosphatase; AR, autosomal recessive; ARF, acute renal
failure; BS, Bartter syndrome; CaSR, calcium-sensing receptor; CRF, chronic renal failure; ESRF, end-stage renal failure; FS, Fanconi syndrome; FSGS, focal segmental
glomerulosclerosis; LMW, low-molecular weight; PTH, parathyroid hormone; RTA, renal tubular acidosis; NC, nephrocalcinosis; UL, urolithiasis; Xr, x-linked recessive.
References are imbedded in table.
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preterm and transplant kidneys containing proliferating
and/or regenerating cells (due to incomplete nephrogenesis
or to ischemia and nephrotoxic immunosuppressants) often
experience crystal retention. Next to epithelial disorders, the
physiological mechanisms of preventing crystal formation
and adhesion can be foiled by high amounts of a soluble
due to (1) hyperabsorption (e.g., in vitamin A/D excess,
chronic inflammatory bowel disease, small bowel syndrome),
(2) overproduction (e.g., primary hyperoxaluria, PH), (3)
deranged epithelium (e.g., infection, prematurity), and (4)
tubular transport defects (several tubulopathies).
RISK FACTORS (UL and NC)
Hypercalciuria
Hypercalciuria is one of the most frequent risk factors for UL
and NC.42–44 There is no sharp limit between normal
(o0.1mmol/kg body weight per day)45,46 and abnormal,
except for very high excretions (40.2mmol/kg per day).
Primary idiopathic hypercalciuria is the most common cause
of calcium-containing stones.3 It has traditionally been
divided into a renal and an absorptive subtype,47 distin-
guished by an elevated fasting urinary calcium excretion in
the renal subtype. Many pediatric patients, however, cannot
easily be classified.
Idiopathic hypercalciuria is considered a multifactorial
disease characterized by a complex interaction of environ-
mental and individual factors. Up to 50% of patients have a
positive family history.48,49 Interestingly, calcium excretion
correlates positively between parents and their progeny and
between siblings, but not between spouses. In addition, it
appears that genetically derived risks are greater than diet-
related risks.
In the search of genes or polymorphisms explaining the
greater susceptibility to renal stone production in patients
with common UL, besides other candidate genes, the
calcium-sensing receptor (CASR) gene was also widely
analyzed. It is located on chromosome 3q13.3-q2 and
encodes for a plasma membrane G-protein-coupled receptor
(Table 1). This receptor is activated by binding calcium
ions on its extracellular domain. It is widely expressed, regu-
lating, e.g., parathyroid hormone secretion, tubular calcium
reabsorption, intestinal calcium absorption, and bone
remodeling.48,49 Activating mutations lead to the autosomal
dominant syndrome of familial hypocalcemia with hyper-
calciuria. Here, hypocalcemia results from inhibiting active
and passive calcium reabsorption in the ascending limb of
Henle’s loop and parathyroid hormone secretion. As bone
density was found to be normal or increased,50 hypercalciuria
seems not to originate from bone. Inactivating mutations of
CASR lead to hypocalciuria and hypercalcemia. Although the
CASR locus was not associated with idiopathic hypercalciuria
or idiopathic calcium UL,51 interesting data of CASR poly-
morphism were described.52 A small but significant (12.6%)
variance in calciuria was explained by a single-nucleotide
polymorphism (SNP) in the CASR gene (990Gly SNP),
which might lead—when activating—to an increased CASR
sensitivity, a decreased calcium reabsorption, and parathyr-
oid hormone secretion.
In the rare but extremely severe X-linked hypercalciuric
nephropathy with tubular proteinuria, Dent’s disease I, early
progressive NC, and renal failure occur.53 Medullary NC
and calcium phosphate stones are common in patients with
distal renal tubular acidosis,54 based on a high urinary pH,
hypercalciuria, and hypocitraturia.55 Medullary NC in com-
bination with cortical NC was described in children with
tyrosinemia. This rare disease, 1:100,000 live births, is often
combined with impaired renal function, aminoaciduria,
hypercalciuria, and tubular acidosis. A variety of other
genetic disorders leading to hypercalciuria are summarized
in Table 1.
There are several clinical entities leading to hypercalcemia
with secondary hypercalciuria and the risk of developing
NC and/or UL. Primary hyperparathyroidism, although the
most frequent cause of hypercalcemic hypercalciuria in adults,
is very rare in children.56,57 Hypervitaminosis D due to
administration of vitamin D-containing multivitamin pre-
parations, vitamin D added to milk preparations, or even
vitamin D prophylaxis in (preterm) infants can induce hyper-
calcemia and hypercalciuria.44 An excessive daily intake of
vitamin A, 410,000 units, may lead to hypercalcemia and
hypercalciuria.58,59 Even short-term immobilization reduces
bone mass of about 15–20% accompanied by hypercalciuria.60
Further reasons are long-term administration of furose-
mide, dexamethasone, or ACTH.61–64 Hypercalciuria is also
found in several syndromes, either linked to the pathogenesis
(Bartter’s syndrome,65 Williams’ syndrome66) or due to renal
tubular damage (Wilsons’ disease, Dent II syndrome;67,68
Table 1). Further conditions include hyper- and hypothyr-
oidism, Cushing syndrome, adrenal insufficiency and meta-
static malignant bone disease, long-term assistant ventilation,
ongoing acid–base changes (metabolic acidosis, reduced bone
density), and long-term parenteral nutrition.69–72
Hyperoxaluria
Hyperoxaluria was shown to be an important promoter of
crystallization.3,70 Urinary oxalate is mostly of endogenous
origin; only B10% derive from the daily nutritional
intake.73,74 Primary causes are distinguished from secondary
ones.
All currently known types of primary hyperoxaluria (PH
I–III) are rare, autosomal recessive diseases of the glyoxylate
metabolism. In PH I, low or absent activity of liver-specific
peroxisomal alanine:glyoxylate aminotransferase (AGT)
causes massive hyperoxaluria.75 PH I is the most frequent
subtype, and the underlying AGXT gene comprising 11 exons
is located on chromosome 2q36–37.76 Diagnosis is mostly
based on complete AGXT sequencing and 4150 mutations
have been identified throughout the gene. The disease
prevalence is approximately two patients per million
population.77 The highly elevated urinary excretion of oxalate
and glycolate (41mmol/1.73m2 body surface area per day,
normal o0.5) causes renal calculi, medullary NC, or both78
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(Figure 1d). With disease progression and declining renal
function, calcium oxalate crystals are systemically depos-
ited.77,78 There is a substantial genetic, biochemical, and
phenotypic heterogeneity ranging from infantile end-stage
renal failure (ESRF) to a late onset or oligosymptomatic
course in advanced adulthood. Unfortunately, most patients
will develop ESRF over time; therefore, early diagnosis is
mandatory, but is all too often delayed.77–80
Primary hyperoxaluria type II (PH II) seems to be even
more rare (about a tenth of the PH I fraction) or remains
markedly underdiagnosed. It is characterized by increased
urinary excretion of oxalate and L-glyceric acid due to a
defect of D-glycerate dehydrogenase and hydroxypyruvate
reductase (GRHPR).81 The GRHPR gene located on chromo-
some 9p11 is composed of 9 exons with 17 currently known
causative mutations.81 The clinical course of PH II is
generally more benign, but symptoms may be clinically
indistinguishable from PH I. ESRF occurs less frequently, has
not been reported in childhood, but still affects about 20% of
adults.82,83
Recently, mutations in a third, 7 exons-spanning gene
(HOGA1 (ref. 84)) on chromosome 10 were found to cause
PH III.85 HOGA1 encodes for a mitochondrial 4-hydroxy-2-
oxoglutarate aldolase. Little is known about the pathogenetic
basis of PH III, but increased glyoxylate generation by
activating mutations was the mechanism proposed.85 What
may be extrapolated (with due caution) from the limited data
available is the fact that this subtype is about to become the
second most frequent form and shows the most favorable
outcome. Although PH III so far has no documented case of
ESRF, initial presentation in infancy with massive uni- or
bilateral nephrolithiasis eventually complicated by urinary
tract infections can be quite severe.
Both the United States (Mayo Clinic Hyperoxaluria
Center) and the OxalEurope PH registries contain still
unclassified patients with the clinical and biochemical
characteristics of PH but negative AGXT, GRHPR, and
HOGA1 analysis. Collaboration with either register is
strongly encouraged and appreciated, as it will substantially
aid in the identification of novel genes in the near future.
Secondary enteric hyperoxaluria
Hyperoxaluria based on increased intestinal oxalate absorp-
tion after bariatric surgery was clearly associated with stone
formation. Although such procedures are (still) uncommon
in children, intestinal surgery may be necessary for other
reasons (e.g., necrotizing enterocolitis). Secondary hyperox-
aluria of childhood is frequently found in patients with
chronic inflammatory bowel disease (e.g., Crohn’s) or with
malabsorption syndromes (cystic fibrosis, celiac disease, a-b
lipoproteinemia, Figure 1c).86–88 Normally, oxalate is intestin-
ally bound to calcium to form insoluble calcium oxalate,
which is not absorbed. In patients with enteric hyperoxaluria,
calcium instead binds to fatty acids, and thus more soluble
oxalate is available for absorption.73 Second, intestinal
oxalate-degrading bacteria, e.g., Oxalobacter formigenes, are
often not found in patients with frequent antibiotic treatment,
e.g., in cystic fibrosis.86 Up to 50% of our patients with cystic
fibrosis have hyperoxaluria and around 11% develop UL or
NC.88 Importantly, enteric hyperoxaluria may also lead to
severe NC and/or recurrent UL,89 even with progression to
ESRF and systemic oxalosis, especially in Crohn’s disease and
short bowel syndrome.90
Hypocitraturia
A low citrate excretion is not always adequately recognized as
a risk factor in the pathogenesis of calcium-containing
stones.91 Low urinary citrate excretion is characteristic of the
complete form of distal renal tubular acidosis.92 Hypoci-
traturia is also observed in persistent mild or latent metabolic
acidosis, in hypokalemia, and in patients with malabsorption
syndromes.88 Idiopathic hypocitraturia may be secondary to
low intestinal alkali absorption.3 Hypocitraturia is the most
important risk factor for stone disease in specific regions of
the world, e.g., in Turkey, and also in risk groups, e.g.
preterm infants.4,32 Therefore, urinary citrate excretion has to
be determined in every patient with stones or NC.
Medication and intoxication
About 1–2% of all kidney stones are drug related.93 Many
patients with drug-induced UL, however, have additional
metabolic abnormalities as risk factors.3 Urinary excretion of
poorly soluble drug components that form stones themselves
or provide a nidus for stone formation is distinguished from
medication increasing the excretion of lithogenic (e.g., loop
diuretics, calcium/vitamin D supplementation) or reducing
the excretion of inhibitory substances (carbonic-anhydrase
inhibitors, topiramate), thus also being risk factors for NC.
For example, hypercalciuria induced by loop diuretics was
reported as one major risk factor in NC of prematurity.64
Inhibition of carbonic anhydrase not only induces hypercal-
ciuria but also hypocitraturia due to metabolic acidosis and
an alkaline urinary pH, both leading to calcium phosphate
precipitation.
Severe hyperoxaluria after intoxication with ethylene
glycol, usually observed after accidental ingestion of anti-
freeze or because of suicide attempts, is based on the
conversion to glycolic acid, formalin, and oxalic acid via
alcohol dehydrogenase. This results in acute renal failure due
to calcium oxalate crystal agglomeration in the renal
parenchyma.94 Diagnostic hints are an extreme anion gap
and abundant calcium oxalate crystals in the urine. Treat-
ment consists of administration of ethanol or 4-methylpyr-
azole to block the alcohol dehydrogenase, bicarbonate to treat
the metabolic acidosis, and hemodialysis to remove both
ethylene glycol and its metabolites.94
Tumor treatment
Recent studies deal with the prevalence of kidney stones in
large cohorts of survivors of childhood acute lymphatic
leukemia, with a prevalence of 0.9% of symptomatic
calcifications95 and a prevalence of 4.5% of asymptomatic
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renal stones.96 As expected, steroid treatment associated with
reduced bone formation, loss of mineral from bone, and
reduced intestinal and renal calcium absorption was a major
determinant for stone formation or NC. Accordingly, Kaste
et al.96 found a negative correlation between asymptomatic
renal calcifications and bone mineral density, yet without
differences in serum or urinary calcium. In addition, tumor
lysis syndrome leading to hyperuricosuria is implicated in
stone formation in tumor patients,97 as well as tubular
damage after chemotherapy.
RISK FACTORS (UL)
Cystinuria
Cystinuria is one of the most frequent genetic disorders with
an overall prevalence of 1:7000 (with data for Europe and the
United States ranging from 1 in 1000 to 1 in 17,000)98,99 and
an autosomal recessive trait (Table 1). Cystinuria is the cause
of up to 10% of all urinary stones in children.100–104 More
than 50% of patients develop bilateral UL, and without
adequate treatment patients will suffer from recurrent stone
formation.103 The majority of patients develop their first
stone during the first two decades of life.104 Cystinuria is
caused by a defective transport of cystine and the dibasic
amino acids lysine, ornithine, and arginine through the
epithelial cells of the renal tubule and the intestinal tract, but
only cystine is insoluble enough to form stones. At pH 48,
cystine solubility is increased threefold.105 Three types of
cystinuria are now distinguished according to the disease-
specific genotype, with type A having the mutation on
chromosome 2, type B on chromosome 19, and type AB with
mutations on both chromosomes.104 Interestingly, there is no
clinical difference based on the different genotypes.
Hyperuricosuria
Uric acid stones are rarely found in children. Hyperuricosuria
results from high-purine diets, myeloproliferative disorders,
tumor lysis syndrome, or enzymatic defects. Many drugs, e.g.,
probenecid, high-dose salicylates, or contrast media, also
increase uric acid excretion. However, low urine pH and low
urine volume are far stronger risk factors for stone formation
than hyperuricosuria per se.
Some rare inherited deficiencies of the purine salvage
enzymes hypoxanthine-guanine-phosphoribosyltransferase
(HPRT) and adenine-phosphoribosyltransferase lead to
primary purine overproduction (Table 1). X-linked Lesch–-
Nyhan syndrome occurs in complete deficiency of HPRT. It is
characterized by mental retardation, automutilation, chor-
eoathetosis, gout, and uric acid NC.106 Partial deficiency of
HPRT results in UL and renal failure.107 Gout and UL were
also reported in glycogen storage disease type I.108
Deficiency of adenine-phosphoribosyltransferase results in
2.8 dihydroxyadeninuria109 with autosomal recessive inheri-
tance. Serum uric acid is normal and the stones are
radiolucent and may be confused with uric acid. The urine
contains characteristic brownish round crystals. Diagnosis is
confirmed by analysis of adenine-phosphoribosyltransferase
activity in red blood cells or of excretion of dihydroxyadenine
in the urine.
In xanthinuria, serum uric acid concentration is very low
because of deficiency of xanthine oxidase, which converts
xanthine to uric acid (Table 1). Characteristic findings of
xanthinuria are an orange-brown urinary sediment or
orange-stained nappies and later xanthine stones.110
Urinary tract infections
Infectious stones are mainly composed of struvite (magne-
sium ammonium phosphate), but often also contain
carbonate apatite, the crystallization of which is favored by
a high urinary pH (47.0). Urease-producing bacteria are
responsible for the formation of struvite calculi. Urea is
hydrolyzed to ammonium ions, which results in a high
urinary pH. Many Gram-positive and Gram-negative bacter-
ia produce urease. However, Proteus species are the
predominant organisms.
Most struvite stones are found in the kidney (Figure 1b),
but they may also form in the bladder. They are mainly seen
in boys under the age of 5 years. In one-third of patients,
there is a primary anomaly of the urinary tract, most often
uretero–pelvic junction obstruction, primary mega-ureter, or,
more rarely, ureterocele or urethral valves.111 Patients with a
neurogenic bladder, particularly those with meningomyocele,
are particularly prone to struvite stones.112 Stones may also
occur during secondary infection on a nidus of different
composition, e.g., cystine or calcium oxalate. It is therefore
important not to miss an underlying metabolic disorder.
Urine stasis increases the risk of crystallization. Stones found
in patients with uretero–pelvic obstruction must therefore
not necessarily be of infectious (or vice versa metabolic)
origin.113
Medication and intoxications
UL due to melamine contamination of powdered milk
formula attracted international attention in 2008 when more
than 50,000 children in the Republic of China suffered from
UL and acute or chronic kidney injury.114 Children exposed
to high-melamine formula displayed a 5.4- to 7.0-fold
increased risk of UL. Melamine is a synthetic chemical added
to milk or animal feed to boost the apparent protein content
because of its high nitrogen content.114,115 Melamine-
contaminated animal food had induced stone outbreaks in
cats and dogs.116 Acute kidney injury was characterized by
necrosis of distal tubular cells, mild inflammation, and intra-
tubular green radial crystals and crystalluria. Chronic toxicity
was associated with larger crystals, interstitial inflammation,
and fibrosis.115,117,118
Indinavir, a protease inhibitor implicated in the treatment
of AIDS, is excreted unchanged in the urine, leading to stone
formation in 2–28% of patients including children. The
stones are composed of indinavir alone or as a mixture, with
indinavir as nidus for calcium-containing stone formation.
As indinavir is poorly soluble at pH 45, urinary acidifica-
tion, increased fluid intake, and, if possible, discontinuation
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of therapy may dissolve stones.119–124 Other medications
precipitating in the urine but rarely causing stones include
ceftriaxone, sulfonamides, ampicillin, amoxicillin, triamte-
ren, acyclovir, and oxypurine.
RISK FACTORS (NC)
Prematurity
Several studies have analyzed factors contributing to the
increased prevalence of NC in preterm infants. Because of
heterogeneous study settings125 and a moderate inter- and
intra-observer variation of ultrasound results, a wide range of
prevalence rates (7–64%) were found.126–135 However, the
more recent studies126,127,133–135 report a lower, but never-
theless high prevalence rate (7–41%).
Nephrogenesis is not complete until 34–36 weeks of
gestational age, and hence the immature renal epithelium
could be a major factor facilitating crystal retention.39 In
addition, premature kidneys have a long loop of Henle and
hence a low urine velocity,125 resulting in crystal aggregation
in the tubules. In fact, NC has been clearly associated with low
gestational age and birth weight.127–130,133,136,137 Gimpel
et al.136 found a 1.65-fold increased risk per 100 g lower birth
weight. In this study, furosemide therapy with 410mg/kg
body weight per day was the strongest independent risk factor
increasing the risk of NC about the factor 48. Whereas some
studies identified furosemide therapy as a major risk
factor,127,133,137 others did not.134 The reduction of passive
calcium reabsorption normally driven by sodium chloride
transport leads to hypercalciuria and may be aggravated by a
slower plasma clearance.138,139 Hypercalciuria itself was
reported to increase the risk of NC about 4.5 times per
mmol/l increase of urinary calcium concentration.136 Hyper-
calcuria in preterm infants has also been associated with high-
dose steroid treatment,133,137,140 whereas other studies did not
identify this as an independent risk factor.136 In particular, in
very low birth weight infants (o1000 g), hypocitraturia was
identified as the major risk factor,137,141 and high intake of
calcium, phosphorus, and ascorbic acid were also reported to
contribute to renal calcification in preterm neonates,137 as
well as gentamicin therapy.133 Interestingly, genetic factors
also seem to have a role, as neonates with a positive family
history of kidney stones, those of male gender, and those of
Caucasian race are more likely to develop NC.132,133
Spontaneous resolution over time in the majority of
preterm infants was reported in recent long-term stu-
dies.131,141–145 A prospective observational study revealed a
35% probability of NC present at term to persist for at least
15 months and a 15% probability to persist for at least 30
months.145 A persistence rate of 10–25% was reported after
7.5 years.143,144 However, all data rely on repeated ultrasound
examinations, whereas true resolution might only be proved
by other imaging methods or kidney biopsy. No difference in
renal function, expressed as glomerular filtration rate levels,
was found at a mean age of 4.7,146 3–6 years127, and 5.8–7.7
years.143 It is noteworthy that prematurity itself can lead to
impaired glomerular filtration rate.143,147
Kidney transplantation
A high prevalence (2–60%) of renal calcifications was reported
in renal transplant patients. Detection rates were profoundly
dependent on the diagnostic procedures.49,148–151 Hypocitra-
turia and the immunosuppressive (nephrotoxic) treatment
per se were reported as risk factors;149,150 however, there is
dispute about its impact on allograft function over time. The
high prevalence (27%) of renal calcification in patients with
delayed graft function152 might be the consequence of more
severe acute tubular necrosis. Pinheiro et al.153 reported a
worse long-term patient, as well as allograft, survival in those
with allograft calcifications present 3 months after transplan-
tation. However, long-term studies are clearly needed to
elucidate the impact of calcifications on allograft function.
CLINICAL PRESENTATION AND DIAGNOSTIC PATHWAY
UL/NC are only the symptom of underlying diseases but not
the disease itself. Thus, a thorough diagnostic evaluation is
required in each child4,154 to start specific treatment as early
as possible. Medical history should include all possible
information about prematurity, concomitant diseases, fluid
intake, diet, vitamin supplementation, and medical treat-
ment. A thorough family history provides information about
potential genetic disorders (see Table 1).
The interpretation of clinical symptoms might be difficult,
especially in younger children. Analogous to adults, most
children present with flank or abdominal pain.1,19,155
However, atypical and nonspecific complaints are more likely
in younger children, especially in those who are not yet able
to articulate their complaints.4,14 A history of UL, nausea,
and vomiting, the presence of flank pain, or more than two
red blood cells per high power field in urine microscopy were
all positively associated with childhood UL.6 NC is mostly
asymptomatic and often only diagnosed when ultrasound is
performed for other reasons. Very frequently, gross or
microscopic hematuria and/or sterile leukocyturia are mis-
interpreted as urinary tract infection.11
The 24-h urine analysis of lithogenic and stone inhibitory
parameters should be regarded as gold standard, although in
the smaller infant spot urine evaluations might only be possible
(Table 2). Diagnostic imaging is first provided by ultrasound of
the kidneys, ureters, and bladder. Even if stones are not visible
on ultrasound (due to overlying with bony structures), a
secondary phenomenon due to obstruction can be visualized.
Unenhanced CTof the abdomen depicts stones more accurately
compared with ultrasound also in pediatric populations.156–158
It is worth mentioning that ultrasound detects 90% of kidney
stones, but only 38% of ureteral stones compared with CT.157
However, in infants and young children, minimization of
exposure to ionizing irradiation and the need for sedation to
perform a CT favor the use of ultrasonography over CT.
TREATMENT
Acute management (UL)
Patients with NC do not normally present with acute
symptoms.4,44 In contrast, patients with acute renal colic
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due to stones present with severe pain, and thus analgetic
treatment has to be initiated directly and in an adequate
dosage. Calcium channel blockers, a-blockers, and cortico-
steroids were shown to induce stone passage.159 Further
management depends on the (ultrasound) evidence of
obstruction due to the stone. In case of persisting obstruc-
tion, impairment of renal function (e.g., due to bilateral
obstruction), or of an acute infection (e.g., pyuria), prompt
removal of the stone is indicated. Initial urine drainage by
nephrostomy tube might be performed to facilitate urine
excretion and to avoid further kidney damage. In the absence
of obstruction, large fluid administration combined with
ongoing application of analgetics, a or calcium channel
blockers combined with steroids is indicated to induce stone
passage.160
Chronic management
Prevention is the main and most important therapeutic
goal! Management of children with NC/UL is mainly based
on the reduction of the solute concentration in the urine.
Independently of the underlying disorder, a high fluid intake
(41.5 to 2 l/1.73m2 body surface area per day) is the
precondition for all further treatments. Fluid intake is
distributed over the whole day providing a stable urinary
excretion rate and avoiding peaks of high concentration levels
of the lithogenic substance. Dietary recommendations have
to be carefully handled. A low calcium diet in calcium stone
formers should be avoided, as it may lead to secondary
hyperoxaluria. However, also a low oxalate diet in those
patients with secondary hyperoxaluria should be restricted to
food with a very high oxalate content, in order to avoid
disturbances of the intestinal interplay of ions resulting
in increased intestinal calcium absorption. An increase in
potassium intake and a decrease in sodium intake can be
recommended, but is often difficult to realize in children.161
Apart from high fluid intake, crystallization inhibitors—
mainly citrate and magnesium—are an effective treatment
option. Citrate is metabolized in the liver to bicarbonate,
resulting in a higher urinary pH and therefore reduced citrate
reabsorption in the renal tubule. Urinary citrate binds to
calcium, forms a soluble complex reducing the precipitation
of calcium with other substances, thus leading to a decreased
urinary saturation index. Urinary calcium excretion can be
reduced by 30% with adequate alkali citrate treatment. Alkali
citrate has been shown to decrease stone production and
reduce progression of NC162,163 (personal experiences). The
recommended daily dosage of alkali citrate is 0.1–0.2 g/kg
body weight (0.3–0.6mmol/kg body weight) in a sodium
potassium or, best, potassium citrate preparation. In patients
with distal RTA, the dosage has to be adapted to the serum
pH and can be given completely as potassium-based solution.
In these children, a minimal dosage of 0.2–0.3 g/kg body
weight is often needed.69 Urine alkalinization increases the
solubility of cystine, uric acid, and calcium oxalate. However,
urinary pH should be monitored, as very high pH levels carry
the risk of calcium phosphate precipitation.T
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Severe hypercalciuria is treated with thiazides. They
reduce renal calcium excretion by increasing calcium uptake
in the distal tubule and stimulate calcium reabsorption in the
proximal tubule via volume control. In particular, in children
with reduced bone density due to hypercalciuria, thiazide
treatment is indicated, as it may improve bone density. A
daily dosage of 0.5–1mg/kg body weight (hydrochlorothia-
zide) is given b.i.d., but side effects such as hypokalemia and
hypotension have to be considered. Here, amiloride as
additional calcium-lowering but potassium-sparing medica-
tion should be added.164
Patients with PH I are treated with pyridoxal phosphate,
a disease-specific chaperone medication (cofactor of the
defective enzyme). Treatment in supra-physiological doses
(5–20mg/kg body weight per day, stepwise increase by 5mg/
kg body weight) helps to reduce the endogenous oxalate
production and hence the urinary oxalate excretion in
approximately a third of patients.79 Noteworthy side effects
are polyneuropathy, but sometimes bullous skin eruptions
as well.
Future treatment options in patients with all types of PH
might include oral administration of intestinal oxalate-
degrading bacteria, e.g., Oxalobacter formigenes. Oral oxalo-
bacter administration was found to be effective in two pilot
trials.165 A recent multicenter trial, however, was unable to
reproduce the striking results in general. Nevertheless,
‘ad hoc’ analyses of a subset of truly compliant patients
suggested an effect when urine oxalate was analyzed by
oxalate to creatinine ratio.166 Next to that, but now in
patients with secondary hyperoxaluria, the oral administra-
tion of oxalate-degrading enzymes might help reduce the
dietary oxalate burden, and thus prevent elevated intestinal
oxalate absorption.
Patients with PH and ESRF should be transplanted as early
as possible, as no renal replacement therapy is capable of
removing sufficient amounts of oxalate. Combined liver–-
kidney transplantation is performed in patients with PH I to
cure the liver-specific enzyme defect. In addition, preemptive
liver transplantation was performed, but timing of the
procedure is difficult because of the clinical heterogeneity
of the disease. Future transplantation options might include
hepatocyte transplantation as a bridging procedure before
combined transplantation, especially in patients with in-
fantile oxalosis. Isolated kidney transplantation is performed
in PH II (the defective enzyme is ubiquitous).
A methionine-restricted diet may be recommended in
patients with cystinuria, as it is metabolized to cystine within
the organism. Methionine is found in protein-rich food;
however, strict protein restriction is not recommended in
children105 and mild protein restriction is difficult to achieve
even in adolescents and adults. Because of the higher solubility
of cystine at urinary pH 48, urine alkalinization is the main
goal of pharmacotherapy. In addition, chelating agents that
cleave the disulfide bond of cystine to cysteine, a homodimer
of cystine, which is 50 times more soluble, will be admini-
stered. D-penicillamine and a-mercaptopropionyl-glycine are
equally effective and used in a dosage of 20–40mg/kg body
weight per day b.i.d. Side effects occurring in 20–50% of
patients including rash, arthralgia, exanthema, thrombocy-
topenia, polymyositis, and nephritic syndrome limit treat-
ment. It is noteworthy that D-penicillamine reduces the level
of pyridoxine, which therefore has to be supplemented.104
Ascorbic acid can reduce cystine to cysteine when adminis-
tered in very high doses; however, there is ongoing debate
about the efficacy.167,168 As high ascorbic acid levels can
increase the endogenous oxalate production and hence
urinary oxalate excretion, this therapy should be avoided in
patients at risk for calcium oxalate stone formation.
Moreover, in patients with purine stones (uric acid, 2,8-
dihydroxyadenine, xanthine), high fluid intake and urine
akalinization to maintain a urinary pH above 6.5 are the
main goals. Protein excess has to be avoided to reduce purine
intake. In cases of refractory hyperuricosuria, allopurinol
(inhibitor of the xathine-oxidase) can be given. Here, careful
dosing regimens are necessary, as allopurinol treatment may
lead to significant xanthinuria. In contrast to uric acid,
xanthine solubility does not increase in alkalinized urine, and
thus citrate is of no effect and fluid intake is the main means
of therapy.110 In patients with 2,8-dihydroxyadenine stones,
urine dilution and allopurinol are, besides dietary restrictions
of adenine and purine, the only therapeutic measures.
Finally, in children with (recurrent) infectious stones, stone
removal and surgical management of a possible anatomic
anomaly are necessary. If stones remain in situ, the next
urinary tract infection will occur after antibiotic treatment is
ceased, as the stone functions as nidus for bacterial growth.
CONCLUSION
The incidence of UL and NC seems to also increase in children
and adolescents. Children with kidney stones or NC, however,
should not be treated like adults. They have to be carefully
examined to unravel the genetic or metabolic background and
to prescribe a proper preventive treatment. It is recommend-
able that specialized pediatric centers take care of children with
rare (metabolic) diseases leading to recurrent kidney stones.
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